Lv2
158 积分 2023-07-07 加入
Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer
1天前
已完结
Phosphoproteomics delineates hepatocellular carcinoma subtypes and pinpoints therapeutic targets
7天前
已完结
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets
8天前
已完结
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
10天前
已完结
Precision surgery for hepatocellular carcinoma
13天前
已完结
LBA50 IMbrave152/SKYSCRAPER-14: A phase III study of first-line tiragolumab (tira) + atezolizumab (atezo) + bevacizumab (bev) vs placebo (pbo) + atezo + bev for patients (pts) with untreated locally advanced or metastatic hepatocellular carcinoma (HCC)
14天前
已关闭
1471MO Adding ipilimumab (IPI) to atezolizumab (ATEZO) plus bevacizumab (BEV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in first-line systemic therapy (1L): PRODIGE 81/FFCD 2101 - TRIPLET HCC
14天前
已完结
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
15天前
已完结
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
16天前
已完结
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling
16天前
已完结
皖公网安备34019202002308
